Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 12 - You Need To See This

Portimao DTM: Muller takes dominant Sunday win for Audi

Audi driver Nico Muller led the second DTM race at Portimao from start to finish to take a convincing victory, as Red Bull’s Felipe Fraga scored his maiden podium in the series.

Motorsport

DTM Portimao: Auer leads Mercedes 1-2 as slow restart dents Bortolotti's charge

Mercedes driver Lucas Auer claimed victory in a dramatic opening race of the 2022 season at Portimao, taking advantage of a slow restart from polesitter Mirko Bortolotti.

Autosport

Audi RS Q8 Signature Edition By ABT Gets 790 HP And All The Carbon Fiber

Limited to 96 units, the 196-mph SUV costs a wallet-wreaking €316,480.

Motor1

From analysis to the latest developments in health,
read the most diverse news in one place.

Porsche's Olsen tops final day of Portimao DTM testing

Dennis Olsen put Porsche on top on the final day of DTM pre-season testing at Portimao, beating the Audi of 10-time race winner Nico Muller.

Autosport

Porsche tops final day of Portimao DTM testing

Dennis Olsen put Porsche on top on the final day of DTM pre-season testing at Portimao, beating the Audi of 10-time race winner Nico Muller.

Motorsport

What Does Raymond James, Wells Fargo Have To Say On Abbott's Q1 Earnings

Raymond James thinks Abbott Laboratories' (NYSE: ABT) 1Q results were solid and demonstrated the durable nature of ABT's portfolio, as three out of four business segments grew over 10% organically, with Nutrition growing 8%

Benzinga

Van der Linde faces "difficult situation" with Rast's DTM return

Kelvin van der Linde faces a “difficult situation” to remain the top dog within the Abt Audi DTM team this season with the arrival of Rene Rast, reckons 2013 champion Mike Rockenfeller.

Autosport

Read news from The Economist, FT, and more,
with one subscription

Abbott Clocks Q1 COVID-19 Test Sales Of $3.3B, Reaffirms FY22 EPS Outlook

Abbott Laboratories (NYSE:ABT) has reported Q1 FY22 adjusted EPS of $1.73, up 31.1% Y/Y, better than the consensus of $1.47 and the management guidance of $1.50. Q1 sales of $11.9 billion increased 13.8% on a reported basis and 17.5% on an organic basis, beating the consensus of $11.02 billion. Worldwide sales, excluding…

Benzinga

5 Ultra-Safe Dividend Aristocrats to Buy in a Market Downturn

Worries over intensifying supply disruptions with growing sanctions on Russia have shaken investors. Furthermore, rising crude oil prices coupled with record-high inflation have given rise to recession fears. Thus, we think it could be wise to bet on ultra-safe dividend aristocrats Johnson & Johnson (JNJ), Walmart (WMT), PepsiCo (PEP), Abbott…

StockNews.com

Abbott Laboratories: Q1 Earnings Insights

Abbott Laboratories (NYSE:ABT) reported its Q1 earnings results on Wednesday, April 20, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga

If You Invested $1000 In Abbott Laboratories 5 Years Ago, Here's How Much You Would Have Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 8.67% on an annualized basis producing an average annual return of 21.94%. Currently, Abbott Laboratories has a market capitalization of $209.78 billion.

Benzinga

Earnings Preview: Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is set to give its latest quarterly earnings report on Wednesday, 2022-04-20. Here's what investors need to know before the announcement. Analysts estimate that Abbott Laboratories will report an earnings per share (EPS) of $1.47.

Benzinga

Abbott Laboratories vs. Zimmer Biomet Holdings: Which Medical Device Stock is a Better Buy?

The medical devices industry is thriving and the integration of advanced technologies position the industry well for growth. Therefore, prominent players in this space, Abbott Laboratories (ABT) and Zimmer Biomet Holdings (ZBH), should benefit. But which of these stocks is a better buy now? Read more to find out.

StockNews.com

Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns. On the macro, investor attention seems to be focused less on revenue growth and more…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

Benzinga

Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.51% on an annualized basis producing an average annual return of 15.1%. Currently, Abbott Laboratories has a market capitalization of $211.63 billion.

Motor1

Audi RS6 Avant Tactical Green With ABT Mods Borders On Perfection

Wagons are boring? Think again.

Benzinga

Abbott Laboratories Whale Trades For March 29

A whale with a lot of money to spend has taken a noticeably bearish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories (NYSE:ABT) we detected 11 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

A Bearish Sign Appears On Abbott Laboratories's Chart

If history is any guide, there may be trouble ahead for shares of Abbott Laboratories (NYSE:ABT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today

Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 3.32% on an annualized basis.

StockNews.com

5 Stocks to Buy for Stable Income in a Volatile Market

Because concerns over high inflation and increasing sanctions on Russia are expected to fuel stock market volatility in the near term, we think it could be wise to bet on dividend aristocrats Johnson & Johnson (JNJ), Procter & Gamble (PG), PepsiCo (PEP), Abbott (ABT), and Becton Dickinson (BDX) for a…

StockNews.com

5 High-Quality Mega-Cap Stocks to Scoop Up Now

In addition to inflationary pressure, economic sanctions imposed on Russia by various countries and corporations in response to Russia’s invasion of Ukraine have exacerbated volatility in the global markets. As investors seek to avoid that volatility and generate stable returns, we think high-quality mega-cap stocks Pfizer (PFE), Cisco (CSCO), Abbott…

Benzinga

Abbott Recalls Baby Formula Manufactured At Michigan facility

Abbott Laboratories (NYSE: ABT) recalls powdered baby formulas, including Similac, made at a Michigan facility after

StockNews.com

3 Diabetes Stocks That are Better Investments Than Senseonics

Despite the ongoing global public health crisis, fundamentally-sound companies focused on diabetic treatments are seemingly unfazed. So, given Senseonics' (SENS) relative overvaluation and bleak growth prospects, we think it could be wise to bet on diabetes stocks Novo Nordisk (NVO), Eli Lilly (LLY), and Abbott Laboratories (ABT). Let’s discuss.

Benzinga

What 5 Analyst Ratings Have To Say About Abbott Laboratories

Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

1 … 10 11 12 13

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.